logo
  

Roivant Forms New Vant With Pfizer To Develop PF-06480605 For Inflammation Diseases

Roivant Sciences (ROIV) and Pfizer Inc. (PFE) Thursday announced formation of a new Vant to develop and commercialize PF-06480605. The company said RVT-3101 is a fully human monoclonal antibody targeting TL1A targeting ulcerative colitis. The drug candidate is currently in Phase 2b development.
RVT-3101 is said to have the potential to provide greater efficacy by hitting multiple inflammatory pathways as well as fibrotic pathways.
Inflammatory bowel diseases are chronic inflammatory diseases of the gastrointestinal tract that affects around two million US adults.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Health insurer Humana Inc. reported Wednesday a net loss for the fourth quarter that slightly widened from last year, hurt primarily by charges associated with productivity initiatives, despite 6.6 percent revenue growth. Adjusted earnings for the quarter topped analysts' expectations, while quarterly revenues missed it by a whisker. South Plainfield, New Jersey-based Two Rivers Coffee is recalling its peanut butter single serve hot chocolate pods citing an undeclared peanut allergen, the U.S. Food Drug Administration said. The recall involves peanut butter single serve hot chocolate pods distributed as "Brooklyn Bean Peanut Butter Cup Hot Cocoa", "Pingo Peanut Butter Cookie Hot Chocolate" and ... Shares of Novartis AG were losing around 2 percent in the early morning trading in Switzerland after the drug major reported Wednesday sharply lower profit in its fourth quarter with weak sales as well as the absence of prior year's hefty Roche income. Adjusted earnings, however, topped market estimates, while top line missed their view. Further, the company announced higher dividend...
RELATED NEWS
Follow RTT